Quantcast

Latest Amgen Inc. Stories

2009-12-06 12:21:00

NEW ORLEANS, Dec. 6 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS). MDS is a pre-leukemic condition in which early blood forming cells in the bone marrow are unable to mature normally, thereby limiting their ability to produce normal mature blood elements, which can lead to low platelet counts. The results of the...

2009-12-01 18:23:00

NEW YORK, Dec. 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis http://www.reportlinker.com/p0166816/The-Future-of-Monoclonal-Antibodies---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html Summary The author has released its latest research "The Future of...

2009-11-30 07:51:00

THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition...

2009-10-19 07:00:00

THOUSAND OAKS, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis. The FDA issues Complete Response Letters to request additional information needed to complete the review of applications for product approval. The Complete Response...

2009-10-16 08:31:00

CHICAGO, Oct. 16 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for COP, AMGN, NFLX, LPL, and PAG. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/101609B (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: ConocoPhillips (NYSE: COP), Amgen Inc. (Nasdaq: AMGN), Netflix, Inc. (Nasdaq: NFLX), LG Display Co., Ltd. (NYSE: LPL), and...

2009-09-14 06:45:00

MINNEAPOLIS and CHICAGO, Sept. 14 /PRNewswire/ -- Sunlight Research((TM)) - The Source for Patent Analysis (www.sunlightresearch.com) today announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio. The Report analyzes the patent claims coverage of 38 US patents owned or controlled by Amgen (Nasdaq: AMGN), and explains how those patents do or do not cover the corresponding technology used in their commercial product Epogen. The technology...

2009-09-13 13:47:00

DENVER, Sept. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR). "These data enhance our understanding of why many women discontinue treatment with current osteoporosis therapies,...

2009-09-10 07:46:00

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Cancer Therapies Market http://www.reportlinker.com/p0109886/World-Cancer-Therapies-Market.html This report analyzes the global market for Cancer Therapies in US$ Billion. The specific product segments analyzed are Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immunotherapy. Annual forecasts for the global market is provided for the period of 2006...

2009-09-08 09:11:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Prescription Drugs http://www.reportlinker.com/p0131233/Prescription-Drugs.html This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class - Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists,...

2009-09-08 09:07:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Small Molecule Kinase Inhibitors http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'